Organoid-Based Screening

Organoid-Based Screening is a cutting-edge physiologically relevant preclinical screening technology, engineering 3D mini-tissues/organs (organoids) from patient-derived or pluripotent stem cells that recapitulate the structural, molecular and functional features of native human organs. Bridging 2D cell culture and in vivo animal models, it enables high-throughput evaluation of drug efficacy, toxicity and personalized response, making it indispensable for target validation, lead optimization and precision medicine research. PharmaAnalytica, a core brand of STEMart, delivers customized organoid screening services with standardized 3D organoid models, high-throughput imaging and automated analysis, accelerating translational drug discovery for oncology, gastroenterology, neurology and other diseases.

Our platform covers a comprehensive portfolio of validated human organoid models, including tumor, liver, intestinal, brain, kidney and lung organoids, all cultured under GMP-compliant conditions to ensure in vivo-like tissue architecture and cellular heterogeneity. By integrating high-throughput compound treatment, real-time phenotypic monitoring and multi-omics analysis, we identify lead compounds with genuine in vivo activity, reduce late-stage clinical attrition and enable the discovery of personalized therapeutic strategies for complex diseases.

Standard Organoid-Based Screening Workflow

Our standardized organoid screening service follows a rigorous 4-phase workflow, generating physiologically relevant and translatable preclinical data for drug discovery:

1. Organoid Model Customization & Preparation: Select or engineer disease-specific human organoid models (patient-derived, stem cell-derived or gene-edited) based on client research goals, and culture them to mature 3D structures with in vivo-like tissue features under GMP-compliant conditions.
2. High-Throughput Compound Treatment: Seed organoids into 96/384-well plates and treat with gradient concentrations of test compounds (hit/lead molecules), setting up vehicle and positive control groups in parallel for standardized drug exposure under optimized culture conditions.
3. Phenotypic Imaging & Quantitative Analysis: Perform automated 3D imaging of drug-treated organoids using the high-content imaging system, capturing fluorescence and brightfield markers of efficacy (e.g., cell proliferation, apoptosis) and toxicity (e.g., organoid degeneration). Use AI software to quantify phenotypic parameters and identify active compounds with desired therapeutic effects.
4. Hit Validation & Mechanistic Elucidation: Conduct secondary validation of primary active compounds with independent replicate experiments and concentration-response analysis. Use the electrophoresis system for molecular analysis, combined with pathway enrichment and multi-omics analysis to elucidate the molecular mechanism of drug action in organoids, and provide a comprehensive screening report with phenotypic, quantitative and molecular data.

PharmaAnalytica's Technology Platform

Advantages of PharmaAnalytica's Organoid-Based Screening Services

Physiologically Relevant 3D Models

Human organoid models recapitulate native organ structure and function, providing more predictive preclinical data than 2D cell culture and reducing species-specific differences vs. animal models.

High-Throughput & Scalable

Supports parallel screening of hundreds to thousands of compounds in 96/384-well formats, meeting the high-throughput demands of early drug discovery and lead optimization.

Customized & Translational Solutions

From organoid model construction and high-throughput screening to hit validation and mechanism analysis, we provide end-to-end services, enabling seamless translation from preclinical research to clinical trials.

GMP-Compliant & Personalized Capabilities

GMP-compliant organoid culture enables clinical-grade research, while patient-derived organoid models support personalized drug response screening for precision medicine development.

Backed by STEMart's strong R&D capabilities and PharmaAnalytica's professional 3D cell culture platform, our Organoid-Based Screening services provide a reliable and translatable preclinical solution for global drug discovery clients. We accelerate the identification of high-quality lead compounds, reduce late-stage clinical attrition and drive the development of precision therapeutics for complex human diseases.